| Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. | |
| | |
MedLine Citation:
|
PMID: 20556668 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A decade has passed since the discovery of angiotensin-converting enzyme 2 (ACE2), a component of the ACE2-angiotensin (Ang)-(1-7)-Mas counterregulatory axis of the renin angiotensin system (RAS). ACE2 is considered an endogenous regulator of the vasoconstrictive, proliferative, fibrotic, and proinflammatory effects of the ACE-Ang II-angiotensin II type 1 receptor (AT(1)R) axis. Both animal and clinical studies have emerged to define a role for ACE2 in pulmonary arterial hypertension (PAH). There is scientific evidence supporting the concept that ACE2 maintains the RAS balance and plays a protective role in PAH. The activation of pulmonary ACE2 could influence the pathogenesis of PAH and serve as a novel therapeutic target in PAH. Current therapeutic strategies and interventions have limited success, and PAH remains a fatal disease. Thus, more research that establishes the novel therapeutic potential and defines the mechanism of the ACE2-Ang-(1-7)-Mas counterregulatory axis in PAH is needed. |
| | |
Authors:
|
Chastity N Bradford; Debra R Ely; Mohan K Raizada |
Related Documents
:
|
16533328 - Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the sh... 7718958 - Pulmonary hypertension and antiphospholipid antibody in a patient with sjögren's syndr... 19466418 - The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension ... 133788 - Pulmonary arterial pulsus alternans secondary to primary pulmonary hypertension. 22527178 - Hybrid treatment of a ruptured aneurysm in the distal aortic arch: report of a case. 10947628 - Heparin-coated stents. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current hypertension reports Volume: 12 ISSN: 1534-3111 ISO Abbreviation: Curr. Hypertens. Rep. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-28 Completed Date: 2011-06-02 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 100888982 Medline TA: Curr Hypertens Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 212-9 Citation Subset: IM |
Affiliation:
|
Department of Physiology and Functional Genomics, College of Medicine, University of Florida, PO Box 100274, Gainesville, FL 32610, USA. cbradford@ufl.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Antihypertensive Agents / therapeutic use* Cardiovascular Diseases / prevention & control Humans Hypertension, Pulmonary / drug therapy*, physiopathology Lung Diseases / drug therapy Peptidyl-Dipeptidase A / drug effects* Renin-Angiotensin System / drug effects* Signal Transduction / drug effects |
| Grant Support | |
ID/Acronym/Agency:
|
T32 HL083810-04/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.17.-/angiotensin converting enzyme 2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chemoradiotherapy in the treatment of inoperable high-grade osteosarcoma.
Next Document: Alterations of cortical GABA neurons and network oscillations in schizophrenia.